Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
AI-Based Cancer Diagnostic Tool Supports Pathologists to Boost Accuracy Efficiency and Access with Joseph Mossel Ibex Medical TRANSCRIPT
Download PDFSep 30, 2024
Joseph Mossel, CEO and Co-Founder of Ibex Medical Analytics is developing AI-based cancer diagnostic technology to help pathologists work faster and more accurately with tissue samples. This technology is being widely adopted as an artificial pathologist that can perform tasks more efficiently and aid the pathologist in reducing error rates, which is ever more important with the shortage of pathologists and increasing demand. Partnering with pharma companies, this technology has the potential to develop algorithms that can help determine the effectiveness of specific cancer drugs, expanding the application of AI beyond improving diagnostic accuracy.
Joseph explains, "Pathology labs know how to receive a biopsy and a tissue sample and then convert it into a slide. Then, it is diagnosed by the pathologist. Our technology, not only does it help the pathologist to do their work faster, but it also is embedded within the lab workflow. You can think of the lab as the kind of a factory here, and we help all of that to be more efficient and faster. In some cases, we can actually cut down the time to diagnosis by even a few days."
"Many studies that we’ve run with pathologists found that using our AI is better than just the AI and better than pathologists not using the AI. And you’ll ask soon better by how much. That depends on the specific pathologists and the lab. But we’ve seen good labs with an error rate of around 2% to 3%. And by error, I mean really missing a cancer diagnosis, so diagnosing a cancerous case as benign. And then the absolute worst we’ve ever seen was a lab where 20% of the cases were misdiagnosed, which was a bit shocking. With a pathologist using our algorithm, the advantage of the two working together is that the algorithm and the pathologist tend to make different mistakes. Working together, we get to a level where there’s maybe a handful of mistakes in every 10,000 cases."
#IbexMedicalAnalytics #CancerDiagnostics #Cancer #DigitalPathology #Pathology #AI #AIinPathology #PatientOutcomes
